Suchergebnisse - "Lim, Chay Ngee"

PubPharm (14)

1

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes : 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

enthalten in: Diabetes care | 2017

von Kazda, C. | Ding, Y. | Kelly, R. | +10

ErratumFor: Diabetes Care. 2016 Jul;39(7):1241-9. - PMID 26681715

2

Phxnlme : An R package that facilitates pharmacometric workflow of Phoenix NLME analyses

enthalten in: Computer methods and programs in biomedicine | 2017

von Lim, C. | Liang, S. | Feng, K. | +4

3

Phxnlme: An R package that facilitates pharmacometric workflow of Phoenix NLME analyses

enthalten in: Computer methods and programs in biomedicine | 2017

von Lim, C. | Liang, S. | Feng, K. | +4

4

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes : 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

enthalten in: Diabetes care | 2016

von Kazda, C. | Ding, Y. | Kelly, R. | +10

CommentOn: Diabetes Care. 2016 Jul;39(7):1241-9. - PMID 26681715

5

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes : 12- and 24-Week Phase 2 Studies

enthalten in: Diabetes care | 2016

von Kazda, C. | Ding, Y. | Kelly, R. | +10

CommentIn: Diabetes Care. 2016 Jul;39(7):1075-7. - PMID 27330122

6

Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers

enthalten in: Journal of clinical pharmacology | 2016

von Lim, C. | Birnbaum, A. | Brundage, R. | +4

7

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

enthalten in: Diabetes care | 2016

von Kazda, C. | Ding, Y. | Kelly, R. | +10

8

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

enthalten in: Diabetes care | 2016

von Kazda, C. | Ding, Y. | Kelly, R. | +10

9

A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients

enthalten in: Clinical pharmacokinetics | 2015

von Lim, C. | Salem, A.

10

A Semi-Mechanistic Integrated Pharmacokinetic/Pharmacodynamic Model of the Testosterone Effects of the Gonadotropin-Releasing Hormone Agonist Leuprolide in Prostate Cancer Patients

enthalten in: Clinical pharmacokinetics | 2015

von Lim, C. | Salem, A.